Teva Pharmaceutical Finance Netherlands III BV
| Industry | Status | Date | Ticker(s) | issuer(s) | MO | SP | FI | Size (M) | Ranking | TNR | Call | MTY | Coupon | Leads | product | Region | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,200 | Sr. Unsecured | 5.25 | - | Jan-32 | 5.25% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,000 | Sr. Unsecured | 7.25 | - | Jan-34 | 5.50% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,000 | Sr. Unsecured | 10.25 | - | Jan-37 | 5.75% | IGC | EMEA | ||||
HLTH | PRCD | May 20, 2025 | TEVA | Teva Pharmaceutical Finance Netherlands II BV, Teva Pharmaceutical Finance Netherlands III BV | Ba1 | BB | BB+ | $500 | Sr. Unsecured | 7.50 | 0.00 | Dec-32 | 6.000% | HYC | EMEA | ||||
HLTH | PRCD | Nov 2, 2021 | TEVA | Teva Pharmaceutical Finance Netherlands II BV, Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB- | BB- | $1,000 | Sr. Unsecured | 5.50 | 0.00 | May-27 | 4.750% | HYC | EMEA | ||||
HLTH | PRCD | Nov 2, 2021 | TEVA | Teva Pharmaceutical Finance Netherlands II BV, Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB- | BB- | $1,000 | Sr. Unsecured | 7.50 | 0.00 | May-29 | 5.125% | HYC | EMEA | ||||
HLTH | PRCD | Nov 19, 2019 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB | - | $1,000 | Sr. Unsecured | 5.00 | - | Jan-25 | 7.125% | HYC | EMEA | ||||
HLTH | PRCD | Mar 6, 2018 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB | - | €700 | Senior | 4.00 | - | Apr-22 | 3.25% | HYC | EMEA | ||||
HLTH | PRCD | Mar 6, 2018 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB | - | $1,250 | Senior | 6.00 | - | Apr-24 | 6.00% | HYC | EMEA | ||||
HLTH | PRCD | Mar 6, 2018 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Ba2 | BB | - | €900 | Senior | 7.00 | - | Mar-25 | 4.50% | HYC | EMEA |